Portola Pharmaceuticals (NASDAQ:PTLA) has been given a $80.00 price objective by analysts at Oppenheimer in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target would indicate a potential upside of 62.50% from the stock’s current price.
PTLA has been the topic of a number of other research reports. Goldman Sachs Group began coverage on shares of Portola Pharmaceuticals in a report on Friday, December 1st. They set a “buy” rating and a $75.00 target price on the stock. Morgan Stanley restated an “overweight” rating and set a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Credit Suisse Group upgraded shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price on the stock in a report on Wednesday, August 23rd. Finally, BidaskClub upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. Portola Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $71.15.
Portola Pharmaceuticals (NASDAQ PTLA) traded down $2.55 during trading hours on Wednesday, reaching $49.23. 1,076,400 shares of the company traded hands, compared to its average volume of 965,242. Portola Pharmaceuticals has a twelve month low of $17.74 and a twelve month high of $67.10. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The business had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $4.71 million. During the same quarter in the previous year, the business posted ($1.64) earnings per share. The firm’s revenue for the quarter was down 58.9% compared to the same quarter last year. analysts predict that Portola Pharmaceuticals will post -4.95 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Portola Pharmaceuticals by 0.9% in the 2nd quarter. BlackRock Inc. now owns 4,071,966 shares of the biopharmaceutical company’s stock worth $228,721,000 after purchasing an additional 37,241 shares in the last quarter. State Street Corp boosted its stake in Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after purchasing an additional 105,207 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Portola Pharmaceuticals by 3.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 744,702 shares of the biopharmaceutical company’s stock worth $40,081,000 after purchasing an additional 26,544 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its stake in Portola Pharmaceuticals by 38.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after purchasing an additional 202,925 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Portola Pharmaceuticals by 17.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 688,092 shares of the biopharmaceutical company’s stock worth $38,650,000 after purchasing an additional 101,046 shares in the last quarter. Institutional investors own 87.45% of the company’s stock.
WARNING: “Portola Pharmaceuticals (PTLA) PT Set at $80.00 by Oppenheimer” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/13/portola-pharmaceuticals-ptla-pt-set-at-80-00-by-oppenheimer.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.